Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.72 USD
Change Today +0.0267 / 3.87%
Volume 2.6M
As of 1:47 PM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

7707 Gateway Boulevard

Suite 140

Newark, CA 94560

United States

Phone: 510-456-4000

Fax: 510-456-4001

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company’s primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. Its major product development program is its Central Nervous System (CNS) Program, in which the company is developing applications for HuCNS-SC cells, its proprietary human neural platform technology. The company is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the CNS. Therapeutic Product Development Programs CNS Program The company’s platform technology, HuCNS-SC cells, is an expanded composition of normal human neural stem cells. Its CNS Program is initially focusing on developing clinical applications in which transplanting HuCNS-SC cells would protect or restore organ function of the patient before such function is irreversibly damaged or lost due to disease progression. Its initial target indications are Pelizeaus-Merzbacher Disease (PMD) and diseases in which deficient myelination plays a central role, such as cerebral palsy or multiple sclerosis; spinal cord injury; Alzheimer’s disease; and disorders in which retinal degeneration plays a central role, such as age-related macular degeneration or retinitis pigmentosa. The company completed a Phase I clinical trial in PMD. In its preclinical research, the company has shown that HuCNS-SC cells differentiate into oligodendrocytes, the myelin producing cells, and produce myelin. The company has transplanted HuCNS-SC cells into the brain of the mutant shiverer mouse, which is deficient in myelin, and shown widespread engraftment of human cells that matured into oligodendrocytes, and that the human oligodendrocytes myelinated the mouse axons. The company completed a six-patient Phase I clinical trial of its HuCNS-SC cells in infantile and late infantile neuronal ceroid lipofuscinosis (NCL), which is a neurodegenerative disorder of the brain. Its preclinical data demonstrate that HuCNS-SC cells, when transplanted in a mouse model of infantile NCL, engraft, migrate throughout the brain, produce the relevant missing enzyme, measurably reduce the toxic storage material in the brain, protect host neurons so that more of them survive, and delay the loss of motor function compared to a control group of non-transplanted mice. The company is conducting a Phase I/II clinical trial to evaluate its HuCNS-SC cells as a treatment for chronic spinal cord injury. The trial is being conducted in Switzerland, Canada, and the United States. The company initiated a Phase I/II clinical trial in dry age-related macular degeneration, the more common form of age-related macular degeneration. The company is also conducting preclinical studies of its HuCNS-SC cells in Alzheimer’s disease. Other CNS Collaborations The company has collaborated on various research programs to assess both the in vitro potential of the HuCNS-SC cells and the effects of transplanting HuCNS-SC cells into various preclinical animal models. One such collaboration is with researchers at the Stanford University School of Medicine that evaluated the company’s human neural stem cells in animal models of stroke. Tools and Technologies Programs In the company’s tools and technologies programs, it is engaged in developing and commercializing applications of its technologies to enable stem cell-based research. The company markets a range of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. Its cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements. Its cell lines available for research use include human neural stem cells and hFB101, ultra primary human fibroblasts for genetic reprogramming. The company’s antibody reagents include STEM24, STEM101, STEM121, and STEM123, which could be used for cell detection, isolation, and characterization. The company also markets various human cell lines for use in research, includi

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $0.72 USD +0.0267

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.30 USD -0.01
Bioheart Inc $0.0050 USD -0.0008
Biorestorative Therapies Inc $0.42 USD 0.00
Cytori Therapeutics Inc $0.67 USD -0.0044
Opexa Therapeutics Inc $0.53 USD -0.044
View Industry Companies

Industry Analysis


Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 45.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at